APP/PS1 Dual Transgenic Mouse Model

The APP/PS1 (also written as APP/PS1 or APP+PS1) double transgenic mouse model is one of the most established and widely used animal models for Alzheimer's disease (AD) research. It expresses mutant forms of both the [amyloid precursor protein (APP)](/genes/app) and [presenilin 1 (PSEN1](/genes/psen1)) genes, leading to progressive amyloid-beta (Aβ) deposition.

Genetic Design

The APP/PS1 (also written as APP/PS1 or APP+PS1) double transgenic mouse model is one of the most established and widely used animal models for Alzheimer's disease (AD) research. It expresses mutant forms of both the [amyloid precursor protein (APP)](/genes/app) and [presenilin 1 (PSEN1](/genes/psen1)) genes, leading to progressive amyloid-beta (Aβ) deposition.

Genetic Design

The APP/PS1 model combines two familial AD mutations:

| Gene | Mutation | Promoter | Expression Level |
|------|----------|----------|------------------|
| [APP](/genes/app) | Swedish (K670N/M671L) | Mouse Prion promoter | ~5-10x endogenous |
| [PSEN1](/genes/psen1) | M146L | Mouse Prion promoter | Endogenous levels |

The Swedish mutation (APP Swedish) is located at the beta-secretase cleavage site and dramatically increases total Abeta production. The PSEN1 M146L mutation alters gamma-secretase activity to favor production of the longer, more aggregation-prone Abeta42 species.

Mechanism of Pathology

Amyloid Generation Cascade

Temporal Progression

• 2-4 months: No significant pathology, baseline behavior
• 6 months: Initial plaque deposits appear in cortex
• 9-12 months: Extensive plaque burden in cortex and hippocampus
• 12+ months: Declining cognitive function, synaptic loss

Pathological Characteristics

Amyloid Deposition

• Plaque distribution: Cortex, hippocampus (CA1, dentate gyrus), subiculum
• Plaque types: Both diffuse and dense-core plaques present
• Plaque morphology: Typical amyloid fibrillar structure on histology
• Vascular amyloid: Some CAA (cerebral amyloid angiopathy) in older mice

Neuroinflammation

• Microgliosis: Activated microglia surrounding plaques, especially in cortex
• [Astrocytes](/cell-types/astrocytes) show reactive gliosis near plaque deposits
• Cytokine upregulation: IL-1β, TNF-α, IL-6 in plaque-rich regions

Synaptic Pathology

• Loss of [synaptic markers](/proteins/synaptophysin) (synaptophysin, PSD95) in hippocampus
• Impaired LTP (long-term potentiation) in hippocampal slices
• Reduced dendritic spine density in CA1 neurons

Cognitive Deficits

• Spatial memory impairments in Morris water maze (detectable at 9-12 months)
• Deficits in contextual fear conditioning
• Working memory deficits in radial arm maze

Research Applications

Therapeutic Testing

The APP/PS1 model is used to test:

Biomarker Studies

• CSF Aβ42 as pharmacodynamic biomarker
• PET amyloid imaging agent validation
• Plasma biomarker correlation with brain pathology

Mechanism Research

• Amyloid-triggered neuroinflammation pathways
• Synaptic dysfunction mechanisms
• Neuronal network hyperactivity in early AD

Advantages and Limitations

Advantages

• Moderate progression: Pathology develops over 6-12 months, allowing therapeutic intervention windows
• Well-characterized: Extensive background literature, standardized protocols
• Robust phenotype: Clear plaque pathology and behavioral deficits
• F1 hybrid background: C57BL6 x C3H background reduces background strain effects

Limitations

• Amyloid-only: Lacks prominent tau pathology (neurofibrillary tangles)
• Overexpression artifact: Prion promoter drives non-physiological expression
• No neuronal loss: Significant neuronal loss not observed despite plaque burden
• Limited gliosis: Less pronounced neuroinflammation than some models

Comparison to Other Models

| Model | Plaque Onset | Tau Pathology | Neuronal Loss | Complexity |
|-------|--------------|---------------|---------------|------------|
| APP/PS1 | 6 months | Minimal | Limited | Dual transgenic |
| 5xFAD | 2 months | Minimal | Some | 5 mutations |
| 3xTg-AD | 6-12 months | Yes (by 12mo) | Yes | Triple transgenic |
| APPDutch | 12+ months | No | No | Single mutation |

Related Pages

• [5xFAD Transgenic Model](/models/5xfad-transgenic-mouse-model) — More aggressive amyloid model
• [3xTG-AD](/mechanisms/3xtg-ad-mouse) — Triple transgenic with both amyloid and tau
• [BACE1 inhibitors](/therapeutics/bace1-inhibitors) — Therapeutic target tested in this model

References

Pathway Diagram

The following diagram shows the key molecular relationships involving APP/PS1 Dual Transgenic Mouse Model discovered through SciDEX knowledge graph analysis: